文献速递系统性红斑狼疮

260例狼疮肾炎患者慢性肾脏病风险:全国多中心队列长达35年随访分析

Risk of chronic kidney disease in 260 patients with lupus nephritis: analysis of a nationwide multicentre cohort with up to 35 years of follow-up.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该多中心观察性研究回顾性分析葡萄牙风湿病登记前瞻性队列中260例活检证实的增殖性、膜性和混合性狼疮肾炎患者,中位随访8年(最长35年)。膜性狼疮肾炎患者基线血肌酐显著低于增殖性组,蛋白尿水平两组无差异。治疗1年时62%达到EULAR/ERA-EDTA完全缓解,另5%达部分缓解;治疗1年时eGFR≤75 mL/min/1.73 m²是进展至慢性肾脏病的最强预测因素(HR 23,95%CI 8-62,P<0.001)。

要点

  • 膜性狼疮肾炎基线血肌酐显著低于增殖性组,蛋白尿水平两组无显著差异。
  • 治疗1年时62%患者达EULAR/ERA-EDTA完全缓解,另5%达部分缓解。
  • 治疗1年时eGFR≤75 mL/min/1.73 m²是进展至慢性肾脏病的最强预测因素(HR 23)。

核心结论

  • 在本队列中,蛋白尿水平不能预测狼疮肾炎的病理学分型。
  • 治疗1年后eGFR≤75 mL/min/1.73 m²对进展至慢性肾脏病有强烈预测作用。

研究设计与样本

  • 多中心观察性研究,对前瞻性队列进行回顾性分析,数据来自葡萄牙风湿病登记-Reuma.pt。
  • 纳入活检证实的增殖性狼疮肾炎、膜性狼疮肾炎和混合性狼疮肾炎患者,共260例。
  • 采用Cox回归生存分析探究慢性肾脏病的预测因素。

主要发现

  • 共纳入260例患者,中位随访8年(IQR 11;最短1年,最长35年)。
  • 膜性狼疮肾炎患者血清肌酐显著低于增殖性组[0.70(IQR 0.20;最小0.50,最大1.30)mg/dl vs 0.80(IQR 0.31;最小0.26,最大2.60)mg/dl,P=0.003]。
  • 蛋白尿水平两组间无差异(P=0.641)。
  • 增殖性组补体水平降低而膜性组接近正常,膜性组抗dsDNA抗体阳性患者更少(P<0.001)。
  • 治疗开始1年后,62%患者达到EULAR/ERA-EDTA完全缓解,另5%达到部分缓解。

关键数值与推荐

  • 诊断时蛋白尿较低的患者更可能实现1年完全肾脏缓解。
  • 诊断时或1年时蛋白尿均不能预测长期慢性肾脏病。
  • 1年时eGFR≤75 mL/min/1.73 m²是进展至慢性肾脏病的最强预测因素(HR 23 [95% CI 8-62],P<0.001)。
  • 其他可能预测因素包括使用硫唑嘌呤诱导缓解、诊断时年龄较大和男性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare proliferative (PLN) and membranous (MLN) lupus nephritis (LN) regarding clinical and laboratory presentation and long-term outcomes, and to investigate predictors of progression to chronic kidney disease (CKD). METHODS: Multicentre observational study, with retrospective analysis of a prospective cohort, using data from the Rheumatic Diseases Portuguese Registry - Reuma.pt. Patients with biopsy-proven PLN, MLN and mixed LN were included. Cox regression survival analysis was used to investigate predictors of CKD. RESULTS: A total of 260 patients were included. Median follow-up was 8 years (IQR 11; minimum 1, maximum 35 years). MLN patients presented with significantly lower serum creatinine [0.70 (IQR 0.20; minimum 0.50, maximum 1.30) mg/dl vs 0.80 (IQR 0.31; minimum 0.26, maximum 2.60) in PLN, P = 0.003]. Proteinuria levels did not differ between groups (P = 0.641). Levels of complement were reduced in PLN but nearly normal in MLN patients, and there were fewer patients with positive anti-dsDNA antibodies in the MLN group (P < 0.001). One year after the beginning of treatment, 62% of the patients achieved EULAR/ERA-EDTA complete response, with a further 5% achieving partial response. Patients with lower proteinuria at diagnosis were more likely to achieve a complete renal response at one year; however, proteinuria at diagnosis or at one year did not predict long-term CKD. Estimated glomerular filtration rate (eGFR) ≤75 mL/min/1.73 m2 at one year was the strongest predictor of progression to CKD (HR 23 [95% CI 8-62], P < 0.001). Other possible predictors included the use of azathioprine for induction of remission, older age at diagnosis and male sex. CONCLUSION: Proteinuria levels did not predict LN histologic class in our cohort. eGFR cutoff of 75 mL/min/1.73 m2 after one year of treatment was strongly predictive of progression to CKD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Farinha F, Barreira S, Couto M, et al. Risk of chronic kidney disease in 260 patients with lupus nephritis: analysis of a nationwide multicentre cohort with up to 35 years of follow-up. Rheumatology (Oxford). 2025. PMID: 38648778. doi:10.1093/rheumatology/keae236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。